PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2054310
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2054310
Disposable Syringes Market is estimated to be valued at USD 10.68 Bn in 2026 and is expected to reach USD 16.93 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.68 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.80% | 2033 Value Projection: | USD 16.93 Bn |
Disposable Syringes are a common tool in the medical and veterinary sciences and are composed of plastic. Disposable syringes are quickly taking the place of traditional glass syringes since they are readily available in sterilized condition, ready to use, and are more affordable. Additionally, the scourge of AIDS has virtually eliminated the reuse of syringes, and the demand for disposable syringes has skyrocketed. Most disposable syringes are made of polypropylene and are injection molded. Syringes come in sizes of 1 ml, 2 ml, 5 ml, and 10.68 ml, come in a variety of shapes, and are either constructed of two or three components. The size and quantity of injection molding machines needed depend on the design of syringes, the number of mold cavities, and the annual production. The high prevalence of chronic diseases, the rising manufacturing, and the rising demand for injectable drugs is expected to boost the global disposable syringes market growth over the forecast period.
The key market players are focusing on adoption of growth strategies such as partnerships, as well as acquisitions, which is attributed to the growth of global disposable syringes market. For instance, in September 2022, ICU Medical, Inc., a medical device company which develops, manufactures, distributes and commercializes devices used in infusion therapy and critical care applications and Smiths Group plc., a diversified technology company announced that ICU Medical has committed to acquire the Smiths Medical division in a transaction that is superior to the existing proposed sale of Smiths Medical to Trulli Bidco Ltd. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies will be a leading infusion therapy company with estimated pro forma combined revenues of approximately US$ 2.5 billion.